study is designed to capture long-term safety and effectiveness data of
the TAXUS Express2 Stent in more complex patients treated in routine
practice. The results will be presented at 1:54 p.m., during a
moderated e-poster session. The Company plans to issue a press release
at this time.
Monday, March 31
-- PROMUS(TM) and TAXUS Stents. Results from the Spirit II Clinical Trial
will be presented by Patrick W. Serruys, M.D., PhD, at 8:00 a.m.,
during a Late Breaking Trial session in Grand Ballroom S100. Dr.
Serruys will provide a two-year data analysis of 300 patients treated
with the XIENCE(TM) V (PROMUS) Stent or the TAXUS Express Stent.
SPIRIT II is a randomized, non-inferiority trial designed to obtain CE
Mark approval for both the XIENCE V and PROMUS Stents. The PROMUS
Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent
System manufactured by Abbott and distributed by Boston Scientific.
The Company plans to issue a press release at this time.
PROENCY European Registry
In February, Boston Scientific announced the start of its PROENCY
(PROMUS(TM), ENdeavor(R) and CYpher(R)) European registry, which is
the first of its kind to observe different 'olimus'-eluting coronary
stents. The study will collect real-life clinical outcome data for
Boston Scientific's PROMUS Everolimus-Eluting Stent and compare them
with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent
and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients
treated in routine clinical practice. Clinical investigators are
currently being recruited for the U.S. phase of PROENCY, which will
begin upon U.S. launch of the PROMUS Stent expected later this year.
-- Biventricular Pacing Percentage in Heart
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved